Articles tagged with Drug Resistance
Researchers have developed an AI model called SyntheMol that can design new antibiotics against deadly bacteria like Acinetobacter baumannii. The model identified six potent antibacterial compounds with non-toxic properties, offering a potential solution to the global crisis of antibiotic resistance.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Researchers at Weill Cornell Medicine found that patients with drug-resistant tuberculosis (TB) respond similarly to those with drug-sensitive TB when treated with bedaquiline-based second-line medications. The study suggests that treatment duration for drug-resistant TB may be shortened, potentially reducing mortality rates.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
A new study shows that inhibiting TACC3 can restore the effectiveness of T-DM1 in HER2-positive breast cancer cells, which have developed resistance. This is achieved by inducing immunogenic cell death and enhancing the response to the drug.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Xylazine, a veterinary medication, has been found in the illicit opioid supply, rendering naloxone ineffective in treating overdose cases. Specialized addictions care remains crucial in addressing underlying substance use disorders.
The University of Texas at Arlington is advancing its understanding of deadly disease tuberculosis (TB) with a new research project led by associate professor Kayunta Johnson-Winters. The project aims to understand why certain types of Mycobacterium tuberculosis bacteria do not respond to treatments.
A new proteogenomics study provides insights into how drug resistance develops in acute myeloid leukemia, offering a potential path forward for treatment. Researchers identified specific proteins and molecular locations that play a key role in determining protein activity, which could help doctors switch to alternative medications.
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
Researchers found that resistant bacteria like Klebsiella pneumoniae and Escherichia coli can remain in the body for up to nine years after initial infection. The study's key findings highlight the need for tailored treatment approaches to combat persistent infections.
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
A recent study has identified a promising solution to combat resistance to protein degraders, which are a novel approach in drug discovery. The researchers found that the drug RBS-10 selectively removes resistant cells by targeting the enzyme NQO1, which is overexpressed in these cells.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.
A new study published in Nature Communications has provided structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum. The research suggests that the drug, TDI-8304, can selectively target and kill resistant parasites, offering hope for more effective treatments against ...
Researchers identified hundreds of genes subject to recent selection in six Candida species, providing valuable knowledge for developing better treatments. The study also found a potential spread of resistance through mating between susceptible and resistant strains.
Researchers analyzed UK and Norway data on antibiotic-resistant bacteria, finding that antibiotic use amplifies the spread, but genetic makeup and environmental pressures are also crucial factors. The study suggests a more nuanced understanding of antibiotic resistance is needed to inform public health interventions.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Researchers at University of Chicago Medical Center discovered a correlation between gut microbiome composition and postoperative infections in liver transplant patients. The study found that metabolites in fecal samples could predict infection risk with high accuracy, providing a potential diagnostic tool.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
The Tokyo University of Science team has created a device that enables the simultaneous evaluation of many cancer cells, allowing for rapid and accurate analysis. The system, called cROT, increases throughput to 2,700 cells per hour, making it more than 100 times faster than traditional methods.
Researchers have identified macrocyclic compounds as a potential solution for targeting proteins critical to tumorigenesis, blocking nearly 80% of cancer's signature characteristic events. Additionally, these small compact molecules can effectively overcome drug resistance by binding to mutant proteins and inhibiting their activities.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Researchers identified a correlation between the HSD3B1 biomarker and resistance to combined hormone therapy and radiotherapy in men with prostate cancer. The study found that high levels of the enzyme led to increased testosterone production, promoting resistance to treatment.
Community antibiotic consumption in the EU increased by 18.8% between 2021 and 2022, reversing a significant decline seen during the pandemic. The resurgence of infections may have contributed to the rebound, but highlights the need for continued prudent use of antibiotics.
Researchers at Memorial Sloan Kettering Cancer Center have found that lung cancer cells retain a 'memory' of their healthy cell counterparts, which could be exploited to improve treatment with KRAS inhibitors. Eliminating these AT1-like cells improves treatment response to the drugs.
Scientists at Texas Biomedical Research Institute found a promising cancer therapy also effectively reduces TB growth, even for drug-resistant bacteria. The therapy combines MCL-1 and BCL-2 inhibitors with antibiotics to control TB up to 98%.
The ORBITA-2 trial found that stenting improves symptoms compared to a placebo procedure, providing evidence-based treatment for stable chest pain. The study suggests updating guidelines for stable coronary artery disease and offers patients and medical teams two treatment strategies with similar benefits.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
The Asian malaria mosquito Anopheles stephensi is spreading drug and diagnostic resistant malaria in Africa, increasing the risk of malaria infections by 270%. Its unique ecology and resistance to insecticides make it challenging for conventional mosquito control tools.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
A study led by the University of Sydney found that many antibiotics for childhood infections have less than 50% effectiveness, leading to thousands of unnecessary deaths globally. The World Health Organization has declared antimicrobial resistance a top public health threat, emphasizing the urgent need for updated guidelines.
Researchers have identified polyalthic acid, a compound in copaiba oil, with potent antibacterial activity against Gram-positive bacteria. The study's findings pave the way for developing alternative medications to combat antimicrobial resistance.
Researchers discovered BMAL1 is significantly upregulated in senescent cells and modulates the senescence program through AP-1. The study highlights a previously unappreciated role of BMAL1 in regulating cellular senescence and circadian clock components.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A University of Melbourne research team is developing an oral therapeutic to restore the activity of common antibiotics used to treat community-acquired bacterial pneumonia. The project aims to combat antibiotic-resistant bacteria and reduce healthcare costs, with potential applications in low- and middle-income countries.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
In Eritrea, a new artemisinin-resistant variant has been detected, accompanied by gene deletions that render rapid diagnostic tests ineffective. This emergence poses a significant threat to malaria control efforts in the Horn of Africa and beyond.
Researchers at Tianjin University have discovered a novel approach to combating multidrug-resistant bacteria, inspired by the selective biocatalytic property of macrophages. The biomimetic intelligent catalysis system, consisting of living macrophages and nanoparticles, shows promise in killing MDR E. coli without harming normal cells.
Researchers have discovered a unique adhesin in Candida auris that enables it to stick to surfaces and cause disease. The study found that this adhesin, SCF1, is essential for colonization and virulence, suggesting a potential target for anti-fungal therapy.
Malaria parasites have developed resistance to artemisinins, a critical treatment for non-severe cases, with devastating consequences. The study found that effectiveness declined by 2025% between 2016 and 2019, highlighting the urgent need for new treatments.
A Boston University-led study identified genetic signatures of TB-susceptible and TB-resistant macrophages, leading to a new approach to tweak the immune system to fight the disease. The research could lead to therapies targeting host immunity to tuberculosis.
Researchers at KAUST discovered that certain combinations of stressors increase gene-transfer rates, while others reduce it. They found synergistic effects from combining stressors like UV light and disinfection chemical byproducts, as well as antagonistic effects from chloroform.
Researchers found that next-generation interventions like triple ACTs resulted in treatment failure counts at least 81% lower than traditional therapies. The study suggests extending treatment courses and using multiple drugs simultaneously may hold treatment failure rates near 10%.
Researchers developed a novel material that self-assembles into micelle structures targeting cancer cell lysosomes, specifically interacting with Cathepsin B. This leads to dysfunctional lysosomes and apoptotic death of cancer cells. The technology promises a new approach to combat drug resistance in cancer treatment.
University of Queensland researchers have identified a novel molecule that could overcome cancer drug resistance and prevent tumour regrowth in cancer patients. The newly discovered molecule is not currently a target for treatment, opening the potential for new drug development to combat this major cause of death in cancer patients.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
A Pittsburgh-based surveillance system detected a drug-resistant Pseudomonas aeruginosa infection linked to artificial tears months before the national public health alert. The findings demonstrate the effectiveness of whole genome sequencing-based surveillance in detecting outbreaks and preventing nationwide cases.
Australian researchers analyzed over 1,300 Golden staph strains, linking specific genes to antibiotic resistance and the bacteria's ability to linger in the bloodstream. The study highlights the diagnostic power of integrating clinical and genomic data to develop targeted solutions for deadly superbug infections.
Scientists have detected new strains of malaria-causing parasites in Ethiopia that are resistant to current treatments and escape detection by common diagnostic tests. The prevalence of these double-resistant parasites is a concern for malaria control and elimination efforts in Africa, where the disease remains endemic.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers discovered that titanium micro-spikes with rough surfaces can effectively kill drug-resistant fungus and Candida species through apoptosis. The findings suggest that these surface features may be a promising approach to combatting superbug resistance.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
A UCF researcher is developing a new antibiotic to treat tuberculosis and related lung infections. The team aims to create potent antimycobacterial agents that can be administered orally and target drug-resistant strains.
Researchers used cryoelectron microscopy to visualize how ribosome-modifying enzymes squeeze RNA nucleotides and alter them, leading to drug resistance. The discovery may lead to the design of new antibiotic therapies targeting these enzymes.